Vitamins and prostate cancer risk

Molecules

Volumn 15, Issue 3, 2010, Pages 1762-1783

  Donkena, Krishna Vanaja ^a   Karnes, R Jeffrey ^a   Young, Charles Y F ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

Folic acid; Prostate cancer; Retinoids; SNP; Vitamins A, B, C, D, and E

Indexed keywords

VITAMIN;

ANIMAL; DISEASE MODEL; HUMAN; MALE; PROSTATE TUMOR; REVIEW; RISK FACTOR;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MALE; PROSTATIC NEOPLASMS; RISK FACTORS; VITAMINS;

EID: 77950366425     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules15031762     Document Type: Review

References (157)

1. Bostwick, D. G.; Burke, H. B.; Djakiew, D.; Euling, S.; Ho, S. M.; Landolph, J.; Morrison, H.; Sonawane, B.; Shifflett, T.; Waters, D. J.; Timms, B. Human prostate cancer risk factors. Cancer 2004, 101, 2371-2490.
2. Klein, E. A. Chemoprevention of prostate cancer. Ann. Rev. Med. 2006, 57, 49-63.
3. Lowe, J. F.; Frazee, L. A. Update on prostate cancer chemoprevention. Pharmacotherapy 2006, 26, 353-359.
4. Lippman, S. M.; Lee, J. J. Reducing the "risk" of chemoprevention: Defining and targeting high risk-2005 AACR Cancer Research and Prevention Foundation Award Lecture. Cancer Res. 2006, 66, 2893-2903.
5. Shukla, S.; Gupta, S. Dietary agents in the chemoprevention of prostate cancer. Nutr. Cancer 2005, 53, 18-32.
6. Thompson, I. M.; Tangen, C. M.; Goodman, P. J.; Lucia, M. S.; Klein, E. A. J. Chemoprevention of prostate cancer. Urology 2009, 182, 499-507.
7. Lipscomb, J. Estimating the cost of cancer care in the United States: A work very much in progress. J. Natl. Cancer Inst. 2008, 100, 607-610.
8. Wiygul, J. B.; Evans, B. R.; Peterson, B. L. Polascik, T. J.; Walther, P. J.; Robertson, C. N.; Albala, D. M.; Demark-Wahnefried, W. Supplement use among men with prostate cancer. Urology 2005, 6, 161-166.
9. Demark-Wahnefried, W.; Peterson, B.; McBride, C.; Lipkus, I.; Clipp, E. Current health behaviors and readiness to pursue life-style changes among men and women diagnosed with early stage prostate and breast carcinomas. Cancer 2000, 88, 674-684.
10. Patterson, R. E.; Neuhouser, M. L.; Henderson, M. M.; Schwartz, S. M., Leanna J. Standish, L. J.; Bowen, D. J. Changes in diet, physical activity, and supplement use among adults diagnosed with cancer. J. Am. Diet Assoc. 2003, 103, 323-328.
11. Velicer, C. M.; Ulrich, C. M. Vitamin and mineral supplement use among US adults after cancer diagnosis: A systematic review. J. Clin. Oncol. 2008, 26, 665-673.
12. Radimer, K.; Bindewald, B.; Hughes, J.; Ervin, B.; Swanson, C.; Picciano, M. F. Dietary supplement use by US adults: Data from the National Health and Nutrition Examination Survey, 1999-2000. Am. J. Epidemiol. 2004, 160, 339-349.
13. Rock, C. L. Multivitamin-multimineral supplements: Who uses them? Am. J. Clin. Nutr. 2007, 85, 277S-279S.
14. Stahl, W.; Sies, H. Bioactivity and protective effects of natural carotenoids. Biochim. Biophys. Acta 2005, 1740, 101-107.
15. Olson, J. A.; Krinsky, N. I. Introduction: The colorful fascinating world of the carotenoids: Important physiologic modulators, FASEB J. 1995, 9, 1547-1550.
16. Krinsky, N. I.; Johnson, E. J. Carotenoid actions and their relation to health and disease. Mol. Aspects Med. 2005, 26, 459-516.
17. Borel, P.; Drai, J.; Faure, H.; Fayol, V.; Galabert, C.; Laromiguiere, M.; Le Moel, G. Recent knowledge about intestinal absorption and cleavage of carotenoids. Ann. Biol. Clin. (Paris). 2005, 63, 165-177.
18. Khachik, F. Distribution and metabolism of dietary carotenoids in humans as a criterion for development of nutritional supplements. Pure Appli. Chem. 2006, 78, 1551-1557.
19. Halliwell, B. Antioxidants in human health and disease, Annu. Rev. Nutr. 1996, 16, 33-50.
20. El-Agamey, A.; Lowe, G. M.; McGarvey, D. J.; Mortensen, A.; Phillip, D. M.; Truscott, T. G.; Young, A. J. Carotenoid radical chemistry and antioxidant/pro-oxidant properties. Arch. Biochem. Biophys. 2004, 430, 37-48.
21. Conn, P. F.; Schalch, W.; Truscott, T. G. The singlet oxygen carotenoid interaction. J. Photochem. Photobiol. B-Biol. 1991, 11, 41-47.
22. Schmidt, R. Deactivation of singlet oxygen by carotenoids: Internal conversion of excited encounter complexes. J. Phys. Chem. 2004, 108, 5509-5513.
23. Woodall, A. A.; Lee, S. W.; Weesie, R. J.; Jackson, M. J.; Britton, G. Oxidation of carotenoids by free radicals: Relationship between structure and reactivity. Biochim. Biophys Acta 1997, 1336, 33-42.
24. Pannala, A. S.; Singh, S.; Rice-Evans, C. Interaction of carotenoids and tocopherols with peroxynitrite. Methods Enzymol. 1999, 301, 319-332.
25. Wertz, K.; Siler, U.; Goralczyk, R. Lycopene: Modes of action to promote prostate health. Arch. Biochem. Biophys. 2004, 430, 127-134.
26. Matos, H. R.; Marques, S. A.; Gomes, O. F.; Silva, A. A.; Heimann, J. C.; Di Mascio, P.; Medeiros, M. H.; Lycopene and beta-carotene protect in vivo iron-induced oxidative stress damage in rat prostate. Braz. J. Med. Biol. Res. 2006, 39, 203-210.
27. Matos, H. R.; Di Mascio, P.; Medeiros, M. H. Protective effect of lycopene on lipid peroxidation and oxidative DNA damage in cell culture. Arch. Biochem. Biophys. 2000, 383, 56-59.
28. Porrini, M.; Riso, P.; Brusamolino, A.; Berti, C.; Guarnieri, S.; Visioli, F. Daily intake of a formulated tomato drink affects carotenoid plasma and lymphocyte concentrations and improves cellular antioxidant protection. Br. J. Nutr. 2005, 93, 93-99.
29. Stacewicz-Sapuntzakis, M.; Bowen, P. E. Role of lycopene and tomato products in prostate health. Biochim. Biophys. Acta 2005, 1740, 202-205.
30. De Flora, S.; Bagnasco, M.; Vainio, H. Modulation of genotoxic and related effects by carotenoids and vitamin A in experimental models: Mechanistic issues. Mutagenesis 1999, 14, 153-172.
31. Sharoni, Y.; Agbaria, R.; Amir, H.; Ben-Dor, A.; Bobilev, I.; Doubi, N.; Giat, Y.; Hirsh, K.; Izumchenko, G.; Khanin, M.; Kirilov, E.; Krimer, R.; Nahum, A.; Steiner, M.; Walfisch, Y.; Walfisch, S.; Zango, G.; Danilenko, M.; Levy, J. Modulation of transcriptional activity by antioxidant carotenoids. Mol. Aspects Med. 2003, 24, 371-384.
32. Palozza, P.; Serini, S.; Maggiano, N.; Angelini, M.; Boninsegna, A.; Di Nicuolo, F.; Ranelletti, F. O.; Calviello, G. Induction of cell cycle arrest and apoptosis in human colon adenocarcinoma cell lines by β-carotene through down-regulation of cyclin A and Bcl-2 family proteins. Carcinogenesis 2002, 23, 11-18.
33. Palozza, P.; Serini, S.; Torsello, A.; Di Nicuolo, F.; Maggiano, N.; Ranelletti, F. O.; Wolf, F. I.; Calviello, G. Mechanism of activation of caspase cascade during beta-carotene-induced apoptosis in human tumor cells. Nutr. Cancer 2003, 47, 76-87.
34. Prasad, V.; Chandele, A.; Jagtap, J. C.; Kumar, P. S.; Shastry, P. ROS-triggered caspase-2 activation and feedback amplification loop in beta-carotene-induced apoptosis. Free Radic. Biol. Med. 2006, 41, 431-442.
35. Liu, C.; Lian, F.; Smith, D. E.; Russell, R. M.; Wang, X. D. Lycopene supplementation inhibits lung squamous metaplasia and induces apoptosis via up-regulating insulin-like growth factor-binding protein 3 in cigarette smoke-exposed ferrets. Cancer Res. 2003, 63, 3138-3144.
36. Sacha, T.; Zawada, M.; Hartwich, J.; Lach, Z.; Polus, A.; Szostek, M.; Zdzi Owska, E.; Libura, M.; Bodzioch, M.; Dembińska-Kieć, A.; Skotnicki, A. B.; Góralczyk, R.; Wertz, K.; Riss, G.; Moele, C.; Langmann, T.; Schmitz, G. The effect of beta-carotene and its derivatives on cytotoxicity, differentiation, proliferative potential and apoptosis on the three human acute leukemia cell lines: U-937, HL-60 and TF-1. Biochim. Biophys. Acta 2005, 1740, 206-214. (Pubitemid 40798231)
37. Brunner, T.; Kasibhatla, S.; Pinkoski, M. J.; Frutschi, C.; Yoo, N. J.; Echeverri, F.; Mahboubi, A.; Green, D. R. Expression of Fas ligand in activated T cells is regulated by c-myc. J. Biol. Chem. 2000, 27, 9767-9772. (Pubitemid 30185211)
38. Klefstrom, J.; Verschuren, E. W.; Evan, G. c-Myc augments the apoptotic activity of cytosolic death receptor signaling proteins by engaging the mitochondrial apoptotic pathway. J. Biol. Chem. 2002, 277, 43224-43232. (Pubitemid 35285708)
39. Bodzioch, M.; Dembinska-Kiec, A.; Hartwich, J.; Lapicka-Bodzioch, K.; Banas, A.; Polus, A.; Grzybowska, J.; Wybranska, I.; Dulinska, J.; Gil, D.; Laidler, P.; Placha, W.; Zawada, M.; Balana-Nowak, A.; Sacha, T.; Kiec-Wilk, B.; Skotnicki, A.; Moehle, C.; Langmann, T.; Schmitz, G. The microarray expression analysis identifies Bax as a mediator of beta-carotene effects on apoptosis. Nutr. Cancer 2005, 51, 226-235. (Pubitemid 40734723)
40. Palozza, P.; Serini, S.; Torsello, A.; Di Nicuolo, F.; Piccioni, E.; Ubaldi, V.; Pioli, C.; Wolf, F. I.; Calviello, G. β-carotene regulates NF-kappaB DNA-binding activity by a redox mechanism in human leukaemia and colon adenocarcinoma cells. J. Nutr. 2003, 133, 381-388. (Pubitemid 36172887)
41. Dulinska, J.; Gil, D.; Zagajewski, J.; Hartwich, J.; Bodzioch, M.; Dembińska-Kieć, A.; Langmann, T.; Schmitz, G.; Laidler, P. Different effect of beta-carotene on proliferation of prostate cancer cells. Biochim. Biophys. Acta 2005, 1740, 189-201. (Pubitemid 40798229)
42. Palozza, P.; Sestito, R.; Picci, N.; Lanza, P.; Monego, G.; Ranelletti, F. O. The sensitivity to beta-carotene growth-inhibitory and proapoptotic effects is regulated by caveolin-1 expression in human colon and prostate cancer cells. Carcinogenesis 2008, 29, 2153-2161.
43. Pasquali, D.; Rossi, V.; Bellastella, G.; Bellastella, A.; Sinisi, A. A. Natural and synthetic retinoids in prostate cancer. Curr. Pharm. Des. 2006, 12, 1923-1929.
44. Aboseif, S. R.; Dahiya, R.; Narayan, P.; Cunha, G. R. Effect of retinoic acid on prostatic development. Prostate 1997, 31, 161-167. (Pubitemid 27225199)
45. Lohnes, D.; Kastner, P.; Dierich, A.; Mark, M.; LeMeur, M.; Chambon, P. Function of retinoic acid receptor gamma in the mouse. Cell 1993, 73, 643-658. (Pubitemid 23159005)
46. Blutt, S. E.; Allegretto, E. A.; Pike, J. W.; Weigel, N. L. 1, 25-dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology 1997, 138, 1491-1497.
47. Pasquali, D.; Rossi, V.; Prezioso, D.; Gentile, V.; Colantuoni, V.; Lotti, T.; Bellastella, A.; Sinisi, A. A. Changes in tissue transglutaminase activity and expression during retinoic acid-induced growth arrest and apoptosis in primary cultures of human epithelial prostate cells. J. Clin. Endocrinol. Metab. 1999, 84, 1463-1469. (Pubitemid 30644416)
48. Young, C. Y.; Murtha, P. E.; Andrews, P. E.; Lindzey, J. K.; Tindall, D. J. Antagonism of androgen action in prostate tumor cells by retinoic acid. Prostate 1994, 25, 39-45.
49. Tokumaru, Y.; Harden, S. V.; Sun, D. I.; Yamashita, K.; Epstein, J. I.; Sidransky, D. Optimal use of a panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma. Clin. Cancer Res. 2004, 10, 5518-5522. (Pubitemid 39100490)
50. Kim, H.; Lapointe, J.; Kaygusuz, G.; Ong, D. E.; Li, C.; van de Rijn, M.; Brooks, J. D.; Pollack, J. R. The retinoic acid synthesis gene ALDH1a2 is a candidate tumor suppressor in prostate cancer. Cancer Res. 2005, 65, 8118-8124. (Pubitemid 41330574)
51. Fang, M. Z.; Chen, D.; Sun, Y.; Jin, Z.; Christman, J. K.; Yang, C. S. Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy. Clin. Cancer Res. 2005, 11, 7033-7063.
52. Mills, P. K.; Beeson, W. L.; Phillips, R. L.; Fraser, G. E. Cohort study of diet, lifestyle, and prostate cancer in Adventist men. Cancer 1989, 64, 598-604.
53. Giovannucci, E.; Rimm, E. B.; Liu, Y.; Stampfer, M. J.; Willett, W. C. A prospective study of tomato products, lycopene, and prostate cancer risk. J. Natl. Cancer Inst. 2002, 94, 391-398.
54. Giovannucci, E.; Ascherio, A.; Rimm, E. B.; Stampfer, M. J, Colditz, G. A.; Willett, W. C. Intake of carotenoids and retinol in relation to risk of prostate cancer. J. Natl. Cancer Inst. 1995, 87, 1767-1776.
55. Cook, N. R.; Stampfer, M. J.; Ma, J.; Manson, J. E.; Sacks, F. M.; Buring, J. E.; Hennekens, C. H.; Beta-carotene supplementation for patients with low baseline levels and decreased risks of total and prostate carcinoma. Cancer 1999, 86, 1783-1792.
56. Heinonen, O. P.; Albanes, D.; Virtamo, J.; Taylor, P. R.; Huttunen, J. K.; Hartman, A. M.; Haapakoski, J.; Malila, N.; Rautalahti, M.; Ripatti, S.; Mäenpää, H.; Teerenhovi, L.; Koss, L.; Virolainen, M.; Edwards, B. K. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: Incidence and mortality in a controlled trial. J. Natl. Cancer Inst. 1998, 90, 440-446.
57. Goodman, G. E.; Schaffer, S.; Omenn, G. S.; Chen, C.; King, I. The association between lung and prostate cancer risk, and serum micronutrients: Results and lessons learned from beta-carotene and retinol efficacy trial. Cancer Epidemiol. Biomarkers Prev. 2003, 12, 518-526.
58. Nomura, A. M.; Stemmermann, G. N.; Lee, J.; Craft, N. E. Serum micronutrients and prostate cancer in Japanese Americans in Hawaii. Cancer Epidemiol. Biomarkers Prev. 1997, 6, 487-491.
59. Chang, S.; Erdman, J. W., Jr.; Clinton, S. K.; Vadiveloo, M.; Strom, S. S.; Yamamura, Y.; Duphorne, C. M.; Spitz, M. R.; Amos, C. I.; Contois, J. H.; Gu, X.; Babaian, R. J.; Scardino, P. T.; Hursting, S. D. Relationship between plasma carotenoids and prostate cancer. Nutr. Cancer 2005, 53, 127-134.
60. Zhang, J.; Dhakal, I.; Stone, A.; Ning, B.; Greene, G.; Lang, N. P.; Kadlubar, F. F. Plasma carotenoids and prostate cancer: A population-based case-control study in Arkansas. Nutr. Cancer 2007, 59, 46-53.
61. Key, T. J.; Appleby, P. N.; Allen, N. E.; Travis, R. C.; Roddam, A. W.; Jenab, M.; Egevad, L.; Tjønneland, A.; Johnsen, N. F.; Overvad, K.; Linseisen, J.; Rohrmann, S.; Boeing, H.; Pischon, T.; Psaltopoulou, T.; Trichopoulou, A.; Trichopoulos, D.; Palli, D.; Vineis, P.; Tumino, R.; Berrino, F.; Kiemeney, L.; Bueno-de-Mesquita, H. B.; Quirós, J. R.; González, C. A.; Martinez, C.; Larrañaga, N.; Chirlaque, M. D.; Ardanaz, E.; Stattin, P.; Hallmans, G.; Khaw, K. T.; Bingham, S.; Slimani, N.; Ferrari, P.; Rinaldi, S.; Riboli, E. Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am. J. Clin. Nutr. 2007, 86, 672-681. (Pubitemid 47435834)
62. Gill, J. K.; Franke, A. A.; Steven Morris, J.; Cooney, R. V.; Wilkens, L. R.; Le Marchand, L.; Goodman, M. T.; Henderson, B. E.; Kolonel, L. N. Association of selenium, tocopherols, carotenoids, retinol, and 15-isoprostane F (2t) in serum or urine with prostate cancer risk: The multiethnic cohort. Cancer Causes Control 2009, 20, 1161-1171.
63. Schenk, J. M.; Riboli, E.; Chatterjee, N.; Leitzmann, M. F.; Ahn, J.; Albanes, D.; Reding, D. J.; Wang, Y.; Friesen, M. D.; Hayes, R. B.; Peters, U. Serum retinol and prostate cancer risk: A nested case-control study in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol. Biomarkers Prev. 2009, 18, 1227-1231.
64. Neuhouser, M. L.; Barnett, M. J.; Kristal, A. R.; Ambroson, e C. B.; King, I. B.; Thornquist, M.; Goodman, G. G. Dietary supplement use and prostate cancer risk in the Carotene and Retinol Efficacy Trial. Cancer Epidemiol. Biomarkers Prev. 2009, 18, 2202-2206.
65. Ahn, J.; Moslehi, R.; Weinstein, S. J.; Snyder, K.; Virtamo, J.; Albanes, D. Family history of prostate cancer and prostate cancer risk in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study. Int. J. Cancer 2008, 123, 1154-1159.
66. Watters, J. L.; Gail, M. H.; Weinstein, S. J.; Virtamo, J.; Albanes, D. Associations between alpha-tocopherol, beta-carotene, and retinol and prostate cancer survival. Cancer Res. 2009, 69, 3833-3841.
67. Das, P. M.; Singal, R. DNA methylation and cancer. J. Clin. Oncol. 2004, 22, 4632-4642.
68. Friso, S.; Choi, S. W. Gene-nutrient interactions in one-carbon metabolism. Curr. Drug Metab. 2005, 6, 37-46.
69. Selhub, J. Folate, vitamin B12 and vitamin B6 and one carbon metabolism. J. Nutr. Health Aging 2002, 6, 39-42.
70. Rossi, E.; Hung, J.; Beilby, J. P.; Knuiman, M. W.; Divitini, M. L.; Bartholomew, H. Folate levels and cancer morbidity and mortality: Prospective cohort study from Busselton, Western Australia. Ann. Epidemiol. 2006, 16, 206-212.
71. Pelucchi, C.; Galeone, C.; Talamini, R.; Negri, E.; Parpinel, M.; Franceschi, S.; Montella, M.; La Vecchia, C. Dietary folate and risk of prostate cancer in Italy. Cancer Epidemiol. Biomarkers Prev. 2005, 14, 944-948. (Pubitemid 40478561)
72. Hultdin, J.; Van Guelpen, B.; Bergh, A.; Hallmans, G.; Stattin, M. Plasma folate, vitamin B12, and homocysteine and prostate cancer risk: A prospective study. Int. J. Cancer 2005, 113, 819-824.
73. Stevens, V. L.; Rodriguez, C.; Pavluck, A. L.; McCullough, M. L.; Thun, M. J.; Calle, E. E. Folate nutrition and prostate cancer incidence in a large cohort of US men. Amer. J. Epidemiol. 2006, 163, 989-996. (Pubitemid 43987590)
74. Johansson, M.; Van Guelpen, B.; Vollset, S. E.; Hultdin, J.; Bergh, A.; Key, T.; Midttun, O.; Hallman, G.; Ueland, P. M.; Stattin, P. One-carbon metabolism and prostate cancer risk: Prospective investigation of seven circulating B vitamins and metabolites. Cancer Epidemiol Biomarkers Prev. 2009, 18, 1538-1543.
75. Figueiredo, J. C.; Grau, M. V.; Haile, R. W.; Sandler, R. S.; Summers, R. W.; Bresalier, R. S, Burke, C. A.; McKeown-Eyssen, G. E.; Baron, J. A. Folic acid and risk of prostate cancer: Results from a randomized clinical trial. J. Nat. Cancer Inst. 2009, 101, 432-435.
76. Ebbing, M.; Bønaa, K. H.; Nygård, O.; Arnesen, E.; Ueland, P. M.; Nordrehaug, J. E.; Rasmussen, K.; Njølstad, I.; Refsum, H.; Nilsen, D. W.; Tverdal, A.; Meyer, K.; Vollset, S. E. Cancer incidence and mortality after treatment with folic acid and vitamin B12. JAMA 2009, 302, 2119-2126.
77. Troen, A. M.; Mitchell, B.; Sorensen, B.; Wener, M. H.; Johnston, A.; Wood, B.; Selhub, J.; McTiernan, A.; Yasui, Y.; Oral, E.; Potter, J. D.; Ulrich, C. M. Unmetabolized folic acid in plasma is associated with reduced natural killer cell cytotoxicity among postmenopausal women. J. Nutr. 2006, 136, 189-194.
78. Cicek, M. S.; Nock, N. L.; Li, L.; Conti, D. V.; Casey, G.; Witte, J. S. Relationship between methylenetetrahydrofolate reductase C677T and A1298C genotypes and haplotypes and prostate cancer risk and aggressiveness. Cancer Epidemiol. Biomarkers Prev. 2004, 13, 1331-1336.
79. Singal, R.; Ferdinand, L.; Das, P. M.; Reis, I. M.; Schlesselman, J. J.; Polymorphisms in the methylenetetrahydro-folate reductase gene and prostate cancer risk. Int. J. Oncol. 2004, 25, 1465-1471.
80. Bai, J. L.; Zheng, M. H.; Xia, X.; Ter-Minassian, M.; Chen, Y. P.; Chen, F. MTHFR C677T polymorphism contributes to prostate cancer risk among Caucasians: A meta-analysis of 3511 cases and 2762 controls. Eur. J. Cancer. 2009, 45, 1443-1449.
81. Marchal, C.; Redondo, M.; Reyes-Engel, A.; Perea-Milla, E.; Gaitan, M. J.; Machuca, J.; Diaz, F.; Caballero, J.; Carnero, J. Association between polymorphisms of folate-metabolizing enzymes and risk of prostate cancer. Eur. J. Surg. Oncol. 2008, 34, 805-810.
82. Muslumanoglu, M. H.; Tepeli, E.; Demir, S.; Uludag, A.; Uzun, D.; Atli, E.; Canturk, K. M.; Ozdemir, M.; Turgut, M. The analysis of the relationship between A1298C and C677T polymorphisms of the MTHFR gene with prostate cancer in Eskisehir population. Genet. Test Mol. Biomarkers 2009, 13, 641-645.
83. Collin, S. M.; Metcalfe, C.; Zuccolo, L.; Lewis, S. J.; Chen, L.; Cox, A.; Davis, M.; Lane, J. A.; Donovan, J.; Smith, G. D.; Neal, D. E.; Hamdy, F. C.; Gudmundsson, J.; Sulem, P.; Rafna, T.; Benediktsdottir, K. R.; Eeles, R. A.; Guy, M.; Kote-Jarai, Z.; UK Genetic Prostate Cancer Study Group. ; Morrison, J.; Al Olama, A. A.; Stefansson, K.; Easton, D. F.; Martin, R. M. Association of folate-pathway gene polymorphisms with the risk of prostate cancer: A population-based nested case-control study, systematic review, and meta-analysis. Cancer Epidemiol. Biomarkers Prev. 2009, 18, 2528-2539.
84. Stevens, V. L.; Rodriguez, C.; Sun, J.; Talbot, J. T.; Thun, M. J.; Calle, E. E. No association of single nucleotide polymorphisms in one-carbon metabolism genes with prostate cancer risk. Cancer Epidemiol. Biomarkers Prev. 2008, 17, 3612-3614.
85. Naidu, K. A. Vitamin C in human health and disease is still a mystery? An overview. Nutr. J. 2003, 2, 7.
86. Wang, M. H.; Abreu-Delgado, Y.; Young, C. Y. Effects of vitamin C on androgen receptor mediated actions in human prostate adenocarcinoma cell line LAPC-4. Urology 2003, 62, 167-171.
87. Meyer, F.; Galan, P.; Douville, P.; Bairati, I.; Kegle, P.; Bertrais, S. Estaquio, C.; Hercberg, S. Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU. VI. MAX trial. Int. J. Cancer 2005, 116, 182-186.
88. Kirsh, V. A.; Hayes, R. B.; Mayne, S. T.; Chatterjee, N.; Subar, A. F.; Dixon, L. B.; Albanes, D.; Andriole, G. L.; Urban, D. A.; Peters, U.; PLCO Trial. Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J. Nat. Cancer Inst. 2006, 98, 245-254.
89. Berndt, S. I.; Carter, H. B.; Landis, P. K.; Hallfrisch, J.; Rohrmann, S.; Metter, E. J.; Platz, E. A. Prediagnostic plasma vitamin C levels and the subsequent risk of prostate cancer. Nutrition 2005, 21, 686-690.
90. Bidoli, E.; Talamini, R.; Zucchetto, A.; Bosetti, C.; Negri, E.; Lenardon, O.; Dal Maso, L.; Polesel, J.; Montella, M.; Franceschi, S.; Serraino, D.; La Vecchia, C. Dietary vitamins E and C and prostate cancer risk. Acta Oncol. 2009, 18, 1-5.
91. Lewis, J. E.; Soler-Vilá, H.; Clark, P. E.; Kresty, L. A.; Allen, G. O.; Hu, J. J. Intake of plant foods and associated nutrients in prostate cancer risk. Nutr. Cancer 2009, 61, 216-224.
92. Ambrosini, G. L.; de Klerk, N. H.; Fritschi, L.; Mackerras, D.; Musk, B. Fruit, vegetable, vitamin A intakes, and prostate cancer risk. Prostate Cancer Prostatic Dis. 2008, 11, 61-66.
93. Gaziano, J. M.; Glynn, R. J.; Christen, W. G.; Kurth, T.; Belanger, C.; MacFadyen, J.; Bubes, V.; Manson, J. E.; Sesso, H. D.; Buring, J. E. Vitamins E and C in the prevention of prostate and total cancer in men: The Physicians' Health Study II randomized controlled trial. JAMA 2009, 301, 52-62.
94. Duconge, J.; Miranda-Massari, J. R.; González, M. J.; Taylor, P. R.; Riordan, H. D.; Riordan, N. H.; Casciari, J. J.; Alliston, K. Vitamin C pharmacokinetics after continuous infusion in a patient with prostate cancer. Ann. Pharmacother. 2007, 41, 1082-1083.
95. Ohno, S.; Ohno, Y.; Suzuki, N.; Soma, G.; Inoue, M. High-dose vitamin C (ascorbic acid) therapy in the treatment of patients with advanced cancer. Anticancer Res. 2009, 29, 809-815.
96. Verrax, J.; Calderon, P. B. Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic. Biol. Med. 2009, 47, 32-40.
97. Frei, B.; Lawson, S. Vitamin C and cancer revisited. Proc. Nat. Acad. Sci. USA 2008, 105, 11037-11038.
98. Chen, Q.; Espey, M. G.; Sun, A. Y.; Pooput, C.; Kirk, K. L.; Krishna, M. C.; Khosh, D. B.; Drisko, J.; Levine, M. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc. Nat. Acad. Sci. USA 2008, 105, 11105-11109.
99. Yeom, C. H.; Lee, G.; Park, J. H.; Yu, J.; Park, S.; Yi, S. Y.; Lee, H. R.; Hong, Y. S.; Yang, J.; Lee, S. High dose concentration administration of ascorbic acid inhibits tumor growth in BALB/C mice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis. J. Transl. Med. 2009, 7, 70.
100. Belin, S.; Kaya, F.; Duisit, G.; Giacometti, S.; Ciccolini, J.; Fontés, M. Antiproliferative effect of ascorbic acid is associated with the inhibition of genes necessary to cell cycle progression. PLoS One. 2009, 4, e4409.
101. Ha, Y. M.; Park, M. K.; Kim, H. J.; Seo, H. G.; Lee, J. H.; Chang, K. C. High concentrations of ascorbic acid induces apoptosis of human gastric cancer cell by p38-MAP kinase-dependent up-regulation of transferrin receptor. Cancer Lett. 2009, 277, 48-54.
102. Riordan, H. D.; Casciari, J. J.; González, M. J.; Riordan, N. H.; Miranda-Massari, J. R.; Taylor, P.; Jackson, J. A. A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P. R. Health Sci. J. 2005, 24, 269-276.
103. Hoffer, L. J.; Levine, M.; Assouline, S.; Melnychuk, D.; Padayatty, S. J.; Rosadiuk, K.; Rousseau, C.; Robitaille, L.; Miller, W. H., Jr. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann. Oncol. 2008, 19, 1969-1974.
104. Borst, P. Mega-dose vitamin C as therapy for human cancer? Proc. Natl. Acad. Sci. USA 2008, 105, E95.
105. Heaney, M. L.; Gardner, J. R.; Karasavvas, N.; Golde, D. W.; Scheinberg, D. A.; Smith, E. A.; O'Connor, O. A. Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res. 2008, 68, 8031-8038.
106. Ingraham, B. A.; Bragdon, B.; Nohe, A. Molecular basis of the potential of vitamin D to prevent cancer. Curr. Med. Res. Opin. 2008, 24, 139-149.
107. Gupta, D.; Lammersfeld, C. A.; Trukova, K.; Lis, C. G. Vitamin D and prostate cancer risk: A review of the epidemiological literature. Prostate Cancer Prostatic Dis. 2009, 12, 215-226.
108. McCullough, M. L.; Bostick, R. M.; Mayo, T. L. Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer. Ann. Rev. Nutr. 2009, 29, 111-132.
109. Mucci, L. A.; Spiegelman, D. Vitamin D and prostate cancer risk-a less sunny outlook? J. Nat. Cancer Inst. 2008, 100, 759-761.
110. Rohan, J. N.; Weigel, N. L. 1Alpha, 25-dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells. Endocrinology 2009, 150, 2046-2054.
111. Gocek, E.; Studzinski, G. P. Vitamin D and differentiation in cancer. Crit. Rev. Clin. Lab. Sci. 2009, 46, 190-209.
112. Krishnan, A. V.; Moreno, J.; Nonn, L.; Malloy, P.; Swam, I.S.; Peng, L.; Peehl, D. M.; Feldman, D. Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer. J. Steroid Biochem. Mol. Biol. 2007, 103, 694-702.
113. Rhee, H. V.; Coebergh, J. W.; Vries, E. D. Sunlight, vitamin D and the prevention of cancer: A systematic review of epide miological studies. Eur. J. Cancer Prev. 2009, Aug. 26, [Epub ahead of print].
114. John, E. M.; Koo, J.; Schwartz, G. G. Sun exposure and prostate cancer risk: Evidence for a protective effect of early-life exposure. Cancer Epidemiol. Biomarkers Prev. 2007, 16, 1283-1286.
115. Schwartz, G. G.; Hanchette, C. L. UV, latitude, and spatial trends in prostate cancer mortality: All sunlight is not the same (United States). Cancer Causes Control. 2006, 17, 1091-1101.
116. John, E. M.; Schwartz, G. G.; Koo, J.; Van Den Berg, D.; Ingles, S. A. Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer. Cancer Res. 2005, 65, 5470-5479.
117. Gilbert, R.; Metcalfe, C.; Oliver, S. E.; Whiteman, D. C.; Bain, C.; Ness, A.; Donovan, J.; Hamdy, F.; Neal, D. E.; Lane, J. A.; Martin, R. M. Life course sun exposure and risk of prostate cancer: Population-based nested case-control study and meta-analysis. Int. J. Cancer 2009, 125, 1414-1423.
118. Trump, D. L.; Chadha, M. K.; Sunga, A. Y.; Fakih, M. G.; Ashraf, U.; Silliman, C. G.; Hollis, B. W.; Nesline, M. K.; Tian, L.; Tan, W.; Johnson, C. S. Vitamin D deficiency and insufficiency among patients with prostate cancer. BJU Int. 2009, [Epub ahead of print].
119. Tretli, S.; Hernes, E.; Berg, J. P.; Hestvik, U. E.; Robsahm, T. E. Association between serum 25 (OH) D and death from prostate cancer. Br. J. Cancer 2009, 100, 450-454.
120. Travis, R. C.; Crowe, F. L.; Allen, N. E.; Appleby, P. N.; Roddam, A. W.; Tjønneland, A.; Olsen, A.; Linseisen, J.; Kaaks, R.; Boeing, H.; Kröger, J.; Trichopoulou, A.; Dilis, V.; Trichopoulos, D.; Vineis, P.; Palli, D.; Tumino, R.; Sieri, S.; Bueno-de-Mesquita, H. B.; van Duijnhove, F. J.; Chirlaque, M. D.; Barricarte, A.; Larrañaga, N.; González, C. A.; Argüelles, M. V.; Sánchez, M. J.; Stattin, P.; Hallman, G.; Khaw, K. T.; Bingham, S.; Rinaldi, S.; Slimani, N.; Jenab, M.; Riboli, E.; Key, T. J. Serum vitamin D and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). Am. J. Epidemiol. 2009, 169, 1223-1232.
121. Ahn, J.; Peters, U.; Albanes, D.; Purdue, M. P.; Abnet, C. C.; Chatterjee, N.; Horst, R. L.; Hollis, B. W.; Huang, W. Y.; Shikan, J. M.; Hayes, R. B.; Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Project Team. Serum vitamin D concentration and prostate cancer risk: A nested case-control study. J. Nat. Cancer Inst. 2008, 100, 796-804.
122. Tseng, M.; Giri, V.; Watkins-Bruner, D.; Giovannucci, E. Dairy intake and 1, 25-dihydroxyvitamin D levels in men at high risk for prostate cancer. Cancer Causes Control. 2009, [Epub ahead of print].
123. Park, S. Y.; Murphy, S. P.; Wilkens, L. R.; Stram, D. O.; Henderson, B. E.; Kolonel, L. N. Calcium, vitamin D, and dairy product intake and prostate cancer risk: The Multiethnic Cohort Study. Am. J. Epidemiol. 2007, 166, 1259-1269.
124. Ahn, J.; Albanes, D.; Berndt, S. I.; Peters, U.; Chatterjee, N.; Freedman, N. D.; Abnet, C. C.; Huang, W. Y.; Kibel, A. S.; Crawford, E. D.; Weinstein, S. J.; Chanock, S. J.; Schatzkin, A.; Hayes, R. B.; Prostate, Lung, Colorectal and Ovarian Trial Project Team. Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. Carcinogenesis 2009, 30, 769-776.
125. Raimondi, S.; Johansson, H.; Maisonneuve, P.; Gandini, S. Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis 2009, 30, 1170-1180.
126. Yin, M.; Wei, S.; Wei, Q. Vitamin D Receptor Genetic Polymorphisms and Prostate Cancer Risk: A Meta-analysis of 36 Published Studies. Int. J. Clin. Exp. Med. 2009, 2, 159-175.
127. Onen, I. H.; Ekmekci, A.; Eroglu, M.; Konac, E.; Yesil, S.; Biri, H. Association of genetic polymorphisms in vitamin D receptor gene and susceptibility to sporadic prostate cancer. Exp. Biol. Med. (Maywood) 2008, 233, 1608-1614.
128. Holick, C. N.; Stanford, J. L.; Kwon, E. M.; Ostrande, E. A.; Nejentsev, S.; Peters, U. Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2007, 16, 1990-1999.
129. Holt, S. K.; Kwon, E. M.; Peters, U.; Ostrander, E. A.; Stanford, J. L. Vitamin D pathway gene variants and prostate cancer risk. Cancer Epidemiol. Biomarkers Prev. 2009, 18, 1929-1933.
130. Mikhak, B.; Hunter, D. J.; Spiegelman, D.; Platz, E. A.; Hollis, B. W.; Giovannucci, E. Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1, 25-dihydroxyvitamin D, and prostate cancer risk. Prostate 2007, 67, 911-923.
131. Chen, L.; Smith, G. D.; Evans, D. M.; Cox, A.; Lawlor, D. A.; J. Donovan, J.; Yuan, W.; Day, I, N. M.; Martin, R. M.; Lane, A.; Rodriguez, S.; Davis, M.; Zuccolo, L.; Collin, S. M.; Hamdy, F.; Neal, D.; Lewis, S. J. Genetic Variants in the Vitamin D Receptor Are Associated with Advanced Prostate Cancer at Diagnosis: Findings from the Prostate Testing for Cancer and Treatment Study and a Systematic Review. Cancer Epidemiol. Biomarkers Prev. 2009, 18, 2874-2881.
132. Gross, C.; Stamey, T.; Hancock, S.; Feldman, D. Treatment of early recurrent prostate cancer with 1, 25-dihydroxyvitamin D3 (calcitriol). J. Urol. 1998, 159, 2035-2039;
133. Blutt, S. E.; Polek, T. C.; Stewart, L. V.; Kattan, M. W.; Weigel, N. L. A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice. Cancer Res. 2000, 60, 779-782.
134. Flanagan, J. N.; Zheng, S.; Chiang, K. C.; Kittaka, A.; Sakaki, T.; Nakabayashi, S.; Zhao, X.; Spanjaard, R. A.; Persons, K. S.; Mathieu, J. S.; Holick, M. F.; Chen, T. C. Evaluation of 19-nor-2alpha-(3-hydroxypropyl) -1alpha, 25-dihydroxyvitamin D3 as a therapeutic agent for androgen-dependent prostate cancer. Anticancer Res. 2009, 29, 3547-3553.
135. Yin, Y.; Ni, J.; Chen, M.; Guo, Y.; Yeh, S. RRR-alpha-vitamin E succinate potentiates the antitumor effect of calcitriol in prostate cancer without overt side effects. Clin. Cancer Res. 2009, 15, 190-200.
136. Trump, D. L.; Muindi, J.; Fakih, M.; Yu, W. D.; Johnson, C. S. Vitamin D compounds: Clinical development as cancer therapy and prevention agents. Anticancer Res. 2006, 26, 2551-2556. (Pubitemid 44155534)
137. Flaig, T. W.; Barqawi, A.; Miller, G.; Kane, M.; Zeng, C.; Crawford, E. D.; Glode, L. M. A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer. Cancer 2006, 107, 266-274. (Pubitemid 44036555)
138. Chan, J. S.; Beer, T. M.; Quinn, D. I.; Pinski, J. K.; Garzotto, M.; Sokoloff, M.; Dehaze, D. R.; Ryan, C. W. A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer. BJU Int. 2008, 102, 1601-1606.
139. Srinivas, S.; Feldman, D. A phase II trial of calcitriol and naproxen in recurrent prostate cancer. Anticancer Res. 2009, 29, 3605-3610.
140. Henner, W. D.; Beer, T. M. A New Formulation of Calcitriol (DN-101) for High-Dose Pulse Administration in Prostate Cancer Therapy. Rev. Urol. 2003, 5, S38-S44.
141. Berruti, A.; Tucci, M.; Mosca, A.; Ardine, M.; Poggio, M.; Saini, A.; Russo, L.; Vana, F.; Dogliotti, L. Could the efficacy of docetaxel in prostate cancer patients be potentiated by concomitant high-dose calcitriol administration? J. Clin. Oncol. 2008, 26, 1900-1901;
142. Beer, T. M.; Ryan, C. W.; Venner, P. M.; Petrylak, D. P.; Chatta, G. S.; Ruether, J. D.; Redfern, C. H.; Fehrenbacher, L.; Saleh, M. N.; Waterhouse, D. M.; Carducci, M. A.; Vicario, D.; Dreicer, R.; Higano, C. S.; Ahmann, F. R.; Chi, K. N.; Henner, W. D.; Arroyo, A.; Clow, F.; ASCENT Investigators. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT Investigators. J. Clin. Oncol. 2007, 25, 669-674. (Pubitemid 350002922)
143. Constantinou, C.; Papas, A.; Constantinou, A. I. Vitamin E and cancer: An insight into the anticancer activities of vitamin E isomers and analogs. Int. J. Cancer 2008, 123, 739-752.
144. Lippman, S. M.; Klein, E. A.; Goodman, P. J.; Lucia, M. S.; Thompson, I. M.; Ford, L. G.; Parnes, H. L.; Minasian, L. M.; Gaziano, J. M.; Hartline, J. A.; Parsons, J. K.; Bearden, J. D., 3rd.; Crawford, E. D.; Goodman, G. E.; Claudio, J.; Winquist, E.; Cook, E. D.; Karp, D. D.; Walther, P.; Lieber, M. M.; Kristal, A. R.; Darke, A. K.; Arnold, K. B.; Ganz, P. A.; Santella, R. M.; Albanes, D.; Taylor, P. R.; Probstfield, J. L.; Jagpal, T. J.; Crowley, J. J.; Meyskens, F. L., Jr.; Baker, L. H.; Coltman, C. A., Jr. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009, 301, 39-51.
145. Stevens, V.; McCullough, M. L.; Diver, W. R.; Rodriguez, C.; Jacobs, E. J.; Thun, M. J.; Calle, E. E. Use of multivitamins and prostate cancer mortality in a large cohort of US men. Cancer Causes Control 2005, 16, 643-650. (Pubitemid 41110954)
146. Coulter, I. D.; Hardy, M. L.; Morton, S. C.; Hilton, L. G.; Tu, W. L.; Valentine, D.; Shekelle, P. G. Antioxidants vitamin C and vitamin E for the prevention and treatment of cancer. J. Gen. Intern. Med. 2006, 21, 735-744. (Pubitemid 43973559)
147. Chan, J. M.; Stampfer, M. J.; Ma, J.; Rimm, E. B.; Willett, W. C.; Giovannucci, E. L. Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol. Biomarkers Prev. 1999, 8, 893-899. (Pubitemid 29508725)
148. Rodriguez, C.; Jacobs, E. J.; Mondul, A. M.; Calle, E. E.; McCullough, M. L.; Thun, M. J. Vitamin E supplements and risk of prostate cancer in US men. Cancer Epidemiol. Biomarkers Prev. 2004, 13, 378-382. (Pubitemid 38737462)
149. Kristal, A. R.; Stanford, J. L.; Cohen, J. H.; Wicklund, K.; Patterson, R. E. Vitamin and mineral supplement use is associated with reduced risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 1999, 8, 887-892. (Pubitemid 29508724)
150. Helzlsouer, K. J.; Huang, H. Y.; Alberg, A. J.; Hoffman, S.; Burke, A.; Norkus, E. P.; Morris, J. S.; Comstock, G. W. Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J. Nat. Cancer Inst. 2000, 92, 2018-2023. (Pubitemid 32045898)
151. Christen, S.; Woodall, A. A.; Shigenaga, M. K.; Southwell-Keely, P. T.; Duncan, M. W. Ames, B. N. Gamma-tocopherol traps mutagenic electrophiles such as NO (X) and complements alpha-tocopherol: Physiological implications. Proc. Nat. Acad. Sci. USA 1997, 94, 3217-3222.
152. Cooney, R. V.; Frank, e A. A.; Harwood, P. J.; Hatch-Pigott, V.; Custer, L. J.; Mordan, L. J. Gamma-tocopherol detoxification of nitrogen dioxide: Superiority to alpha-tocopherol. Proc. Nat. Acad. Sci. USA 1993, 90, 1771-1775.
153. Ju, J.; Picinich, S. C.; Yang, Z.; Zhao, Y.; Suh, N.; Kong, A. N.; Yang, C. S. Cancer Preventive Activities of Tocopherols and Tocotrienols. Carcinogenesis 2009, [Epub ahead of print].
154. Takahashi, S.; Takeshita, K.; Seeni, A.; Sugiura, S.; Tang, M.; Sato, S. Y.; Kuriyama, H.; Nakadate, M.; Abe, K.; Maeno, Y.; Nagao, M.; Shirai, T. Suppression of prostate cancer in a transgenic rat model via gamma-tocopherol activation of caspase signaling. Prostate 2009, 69, 644-651.
155. Barve, A.; Khor, T. O.; Nair, S.; Reuhl, K.; Suh, N.; Reddy, B.; Newmark, H.; Kong, A. N. Gamma-tocopherol-enriched mixed tocopherol diet inhibits prostate carcinogenesis in TRAMP mice. Int. J. Cancer 2009, 124, 1693-1699.
156. Wright, M. E.; Weinstein, S. J.; Lawson, K. A.; Albanes, D.; Subar, A. F.; Dixon, L. B.; Mouw, T.; Schatzkin, A.; Leitzmann, M. F. Supplemental and dietary vitamin E intakes and risk of prostate cancer in a large prospective study. Cancer Epidemiol. Biomarkers Prev. 2007, 16, 1128-1135. (Pubitemid 46984948)
157. Bjelakovic, G.; Nikolova, D.; Gluud, L. L.; Simonetti, R. G.; Gluud, C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: Systematic review and meta-analysis. JAMA 2007, 297, 842-857.